DisruptingNRG1binding to ERBB3 or impacting ERBB2/ERBB3 heterodimerization can reduce the volume ofNRG1fusion tumors in various solid tumors.3NRG1is an emerging oncogenic driver and a potential therapeutic target, but no approved targeted drugs are available forNRG1fusion tumors.NRG2fusion has also been found in lung adenocarcinoma patients, but further understanding of its biological functions is needed.4, 5. Here, ERBB3 is linked to lung adenocarcinoma.